Quince Therapeutics, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Quince Therapeutics changed its name to IRulya Therapeutics effective October 9, 2026, and begins trading on Nasdaq under ticker 'IRLA' on October 12, 2026. The company completed a May 2026 merger with Orphai Therapeutics and concurrent private placement raising ~$115 million gross proceeds. Leadership restructured: Brigette Roberts (CEO, ex-Orphai CEO), John Militello (CFO, $440k base + 1.6M RSUs vesting over 4 years), Keith Fandrick (COO, $450k base). Board expanded with five new directors. Cash balance of $116 million as of June 30, 2026 expected to fund operations through end of 2028. Core asset is LAM-001 (inhaled rapamycin) in Phase 2 trials for three pulmonary indications. Prior CEO Dirk Thye and COO Brendan Hannah resigned.
Why this rating
Major strategic pivot post-acquisition with new management, $115M capital raised (180% of company's $64M market cap), focused pipeline asset, and extended runway through 2028. Transformational for shareholder composition and strategy, but execution risk on clinical trials and cash burn remain material.
Tradability signal
SHORT
conviction 20/100 · expected -0.54% over 4 hrs
SHORT (fade the pop): stock already ran +5.2% on this news, and positive calls in this cell have historically given the pop back (-0.62% over 4 hrs, n=182). Reversion play, lower conviction by design. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $30.90 | +10 min · unknown $30.35 ▼ 1.78% | +30 min · unknown $30.20 ▼ 2.27% | +1 hr · unknown $30.20 ▼ 2.27% | +4 hrs · unknown $34.38 ▲ 11.25% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.